Terpenoid Therapeutics, Inc. is a privately-held biotechnology company focused on anti-cancer therapeutics. We use the platform of terpene chemistry to develop candidate drug molecules. Our team is creating, testing, and developing novel drug candidates using cutting-edge technologies. We seek to generate a robust pipeline of terpene-derived therapeutic agents. Two projects are in advanced preclinical testing with lead compounds identified in both projects.
Terpenoid's bisphosphonate project is based on proprietary terpenoid-modified bisphosphonate inhibitors of geranylgeranyl diphosphate synthase (GGDPS), a novel target for which there are currently no approved drugs. Terpenoid predicts that inhibition of GGDPS will result in efficacy in the treatment of primary tumors and metastases (including, but not limited to, bone metastases).
Terpenoid's schweinfurthin project is focused on discovering and developing a drug with activity against primary tumors and metastases. This project is based on rare schweinfurthin natural products whose unique profile of anti-cancer activity was first reported by the National Cancer Institute in 1998